ATE309382T1 - Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse - Google Patents

Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse

Info

Publication number
ATE309382T1
ATE309382T1 AT97914375T AT97914375T ATE309382T1 AT E309382 T1 ATE309382 T1 AT E309382T1 AT 97914375 T AT97914375 T AT 97914375T AT 97914375 T AT97914375 T AT 97914375T AT E309382 T1 ATE309382 T1 AT E309382T1
Authority
AT
Austria
Prior art keywords
gene therapy
recombinant adenovirus
human cancers
adenovirus vectors
disclosed
Prior art date
Application number
AT97914375T
Other languages
English (en)
Inventor
Falleur Boon
Marie-Therese Duffour
Hedi Haddada
Christophe Lurquin
Michel Perricaudet
Catherine Uyttenhoveghesquiere
Guy Warnier
Original Assignee
Aventis Pharma Sa
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa, Ludwig Inst Cancer Res filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE309382T1 publication Critical patent/ATE309382T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97914375T 1996-03-14 1997-03-12 Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse ATE309382T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9603207A FR2746110B1 (fr) 1996-03-14 1996-03-14 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
PCT/FR1997/000435 WO1997034009A1 (fr) 1996-03-14 1997-03-12 Vecteurs adenoviraux recombinants pour la therapie genique des tumeurs humaines

Publications (1)

Publication Number Publication Date
ATE309382T1 true ATE309382T1 (de) 2005-11-15

Family

ID=9490181

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97914375T ATE309382T1 (de) 1996-03-14 1997-03-12 Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse

Country Status (19)

Country Link
US (1) US20030082150A1 (de)
EP (1) EP0889969B1 (de)
JP (1) JP2000507229A (de)
KR (1) KR19990087718A (de)
CN (1) CN1218512A (de)
AT (1) ATE309382T1 (de)
AU (1) AU732288B2 (de)
BR (1) BR9707994A (de)
CA (1) CA2248612A1 (de)
CZ (1) CZ295967B6 (de)
DE (1) DE69734574T2 (de)
DK (1) DK0889969T3 (de)
ES (1) ES2252779T3 (de)
FR (1) FR2746110B1 (de)
HU (1) HUP9902150A3 (de)
IL (1) IL126152A0 (de)
NO (1) NO984052L (de)
SK (1) SK124698A3 (de)
WO (1) WO1997034009A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4668797A (en) * 1996-10-07 1998-05-05 Ludwig Institute For Cancer Research Replication-defective adenoviruses for cancer immunotherapy
CA2388337C (en) 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US7306792B2 (en) * 2001-03-27 2007-12-11 New York University Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
ES2290449T3 (es) 2002-04-09 2008-02-16 Sanofi Pasteur Limited Acido nucleico de cea modificado y vectores de expresion.
JP2005523942A (ja) * 2002-04-30 2005-08-11 アヴィオル セラピューティクス インコーポレイテッド 免疫療法のためのアデノウイルスベクター
CN1327000C (zh) * 2002-09-06 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 靶向黑色素瘤的可复制性腺病毒穿梭载体及腺病毒
EP1556082A1 (de) * 2002-10-22 2005-07-27 Aventis Pasteur Limited Impfstoffe gegen krebs mit hochdosierten zytokinen als adjuvans
CA2550583C (en) * 2003-10-08 2013-01-15 Sanofi Pasteur, Inc. Modified cea /b7 vector
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
EP3532082A4 (de) 2016-12-12 2020-08-26 Salk Institute for Biological Studies Auf tumoren gerichtete synthetische adenoviren und verwendungen davon
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
SK282843B6 (sk) * 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom

Also Published As

Publication number Publication date
IL126152A0 (en) 1999-05-09
DK0889969T3 (da) 2006-03-27
KR19990087718A (ko) 1999-12-27
DE69734574T2 (de) 2006-07-13
US20030082150A1 (en) 2003-05-01
SK124698A3 (en) 1999-05-07
CN1218512A (zh) 1999-06-02
AU2164197A (en) 1997-10-01
EP0889969B1 (de) 2005-11-09
FR2746110A1 (fr) 1997-09-19
NO984052D0 (no) 1998-09-03
DE69734574D1 (de) 2005-12-15
HUP9902150A2 (hu) 1999-11-29
WO1997034009A1 (fr) 1997-09-18
CA2248612A1 (fr) 1997-09-18
ES2252779T3 (es) 2006-05-16
BR9707994A (pt) 1999-07-27
CZ291598A3 (cs) 1998-12-16
JP2000507229A (ja) 2000-06-13
NO984052L (no) 1998-09-03
EP0889969A1 (de) 1999-01-13
AU732288B2 (en) 2001-04-12
CZ295967B6 (cs) 2005-12-14
FR2746110B1 (fr) 1998-04-17
HUP9902150A3 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
ATE309382T1 (de) Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
DE69630890D1 (de) Peptid-immitierende substanzen in der krebstherapie
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
MY119276A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
HUP0203035A2 (hu) Prosztatarák terápiájára és diagnózisára alkalmas vegyületek és eljárások
MXPA03001389A (es) Composiciones y metodos para la terapia y diagnostico de malignidades asociadas con her-2/neu.
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
NO20004631L (no) Forbindelser og fremgangsmÕter for terapi og diagnose av lungekreft
ATE295853T1 (de) Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
YU65103A (sh) Peg-konjugati hgf-nk4
AR019844A1 (es) Polipeptidos composicion farmaceutica, procedimiento para preparar dicha composicion metodo para tratar y prevenir el cancer y metodo para inhibir elcrecimiento de celulas tumorales
ATE514780T1 (de) Zusammensetzungen für die therapie und diagnose von brustkrebs und verwendung davon
DK1007717T3 (da) Metoder og sammensætninger til cancerterapi under anvendelse af gener, der koder for interferon-beta
NO991653D0 (no) Immunogenisk tumor frigjorte partikler (TLP)-blanding
ATE193451T1 (de) Verotoxin pharmazeutische zusammensetzungen und damit medizinische behandlungen
EP2295578A3 (de) Cyp1b1-Nukleinsäuren und Verwendungsverfahren dafür

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0889969

Country of ref document: EP

REN Ceased due to non-payment of the annual fee